CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--f-Star Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb²™) antibodies, today announces that Eliot Forster, Chief Executive Officer, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on Monday August 10, 2020.

Event: F-star Therapeutics Fireside Chat
Time: 1:00 - 1:25 PM ET | 6:00 - 6:25 PM BST
Webcast Link: F-star Therapeutics Fireside Chat

The Company will also be available for one to one meetings during the conference, on Monday August 10 and Tuesday August 11.

- END-

About F-star Therapeutics Ltd

F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005462/en/